prostate research

New research from Dan George, MD, & team emphasizes the importance of diversity in clinical trials after finding a particular drug combo was more successful in Black men.

A biomarker developed with digitalized pathology and AI identified which men treated with radiation for high-risk localized prostate cancer could benefit with short-term drug treatment.

DCI is among the first in the nation to offer a targeted radiopharmaceutical therapy for men with advanced prostate cancer that's progressed on other treatments.

Study results set the stage for use of a liquid biopsy of circulating tumor cells to help identify men who could benefit from PSMA-targeted therapy.

Retired Colonel and DCI member Judd Moul, MD, has been named to receive a Distinguished Contribution Award from the American Urological Association.

DCI biostatistician and professor Susan Halabi, PhD, received, from the University of Alabama, an award for Outstanding Achievement by a Woman in Statistical Sciences.

The DCI Center for Prostate & Urologic Cancers invites the community to an educational symposium and their 4th Tackle Cancer Tailgate on Sept.16 and 17.

Join us at Lincoln Community Health Center (Sat.) and Duke Primary Care Croasdaile (Sun.) for the return of DCI's Men's Health Screening event.

Furong Huang PhD, a postdoctoral fellow in the Wang Lab, received a Department of Defense Prostate Cancer Research Program Early Investigator Award.

Join us for an educational symposium on prostate and urologic cancers on Nov. 5 & the return of the Tackle Cancer Tailgate on Nov. 6.

On Sept. 14, the DCI Office of Health Equity hosted "Barbershop Talk—  Let's Have a Man to Man Discussion About Prostate Cancer."

Astellas Pharma Inc. announced on May 4 that the European Commission has approved enzalutamide for adult men with metastatic hormone-sensitive prostate cancer.

Enrolling a large number of Black men, Duke researchers found potential new paths for improved studies and treatments.

This OHE-hosted talk featured director of the Patierno/George/Freedman Lab Jennifer Freedman, PhD, and postdocs Tyler Allen, PhD, and Sean Piwarski, PhD.

Various genetic alterations in circulating tumor cells were associated with clinical outcomes and resistance to hormone therapy in patients with mCRPC.

The finding points toward a new approach that directly targets the cancer’s fuel source.

In the age of Covid, Community Outreach & Engagement at DCI comes of age, team expands with disparities researcher/associate director

Susan Halabi, PhD, is co-leading a project to create a large international registry of data from prostate cancer patients treated with various PARP inhibitors.

DCI pathologist Jung Wook Park, PhD, mentored by Jiaoti Huang, MD, PhD, and Andrew Armstrong, MD, MSc, has received a Prostate Cancer Foundation Young Investigator Award.

If mothers, sisters and daughters have a history of breast and ovarian cancers, a man's risk for prostate cancer is also significantly increased.

Drug tested in lab studies halts cancer cells that are impervious to hormone therapy.

Andrew Armstrong, MD, found that treatment with enzalutamide and ADT significantly reduced the risk of metastasis or death over time in men with mHSPC.

When Robert “Bob” List, 73, a retired colonel with the U.S. Marine Corps, was diagnosed with stage 2 prostate cancer, he immediately began to research the “enemy” threat.

Black men are underrepresented in clinical trials for prostate cancer, despite an almost two-fold greater incidence and mortality of disease in black versus white populations.